Every man over the age of 45 is at risk for prostate cancer. Two-dimensional (2D) trans rectal ultrasound (TRUS) guided biopsy is the standard method for prostate cancer diagnosis. A critical problem of this TRUS- guided biopsy approach is its significant sampling error and its low sensitivity (24%-52%). Current biopsy approaches may miss up to 30% of prostate cancer. Nevertheless, more than 1.2 million prostate biopsies are performed in each year and the biopsy cost is more than two billion dollars. Innovative image-guided biopsy technology that can improve cancer detection can have significant impact on the management of this disease that affects one in six men. The objective of the proposed study is to evaluate a new, molecular image directed, three-dimensional (3D) ultrasound guided biopsy system in human patients. At our NIH-funded Emory Molecular and Translational Imaging Center, it has been shown that PET/CT imaging with a new, PET molecular imaging agent i.e., FACBC, is more sensitive than the FDA-approved SPECT/CT in prostate cancer detection. FACBC images showed higher focal uptake in tumor foci than in normal prostate and thus could be ideal information to direct targeted biopsy of the prostate. This newly developed biopsy system has a unique feature that FACBC PET/CT images can be registered with 3D ultrasound images, as a result, a suspicious PET lesion is superimposed over the real-time ultrasound data;and the fused image is then used to direct biopsy needles to tumor targets. The hypothesis of the study is that FACBC PET/ultrasound fusion guided biopsy can detect more cancer per core than the standard 12-core TRUS guided biopsy.
The specific aims i nclude: 1) To develop the workflow for performing deformable registration and fusion of FACBC PET/CT and 3D ultrasound images of human patients, and 2) To perform FACBC PET/CT directed, 3D ultrasound-guided biopsy and determine if targeted fusion biopsy can detect more cancer than 2D TRUS-guided biopsy. Thirty six patients, who have suspicion of recurrent prostate cancer after definitive therapy such as radiotherapy, will be recruited into this study. Approximately hal of the patients will have positive imaging findings and will undergo 2D TRUS-guided biopsy as well as PET/ultrasound fusion biopsy. The proposed study will be the first-in-human trial that uses PET/CT imaging to direct 3D ultrasound-guided biopsy of the prostate. The multimodality imaging approach will combine the high sensitivity from PET and real-time information from ultrasound for improved cancer detection. This early-phase clinical trial will help transform the field from the current """"""""blind"""""""" biopsy to future """"""""targeted"""""""" biopsy and result in the change of prostate cancer management. The new biopsy technology can have an immediate impact on patient care by improving the detection and diagnosis of prostate cancer.

Public Health Relevance

This study aims to improve prostate cancer detection by using a new molecular imaging technology and by using a new three-dimensional image-guided system. By bringing PET/CT to the ultrasound suite, allowing highly sensitive imaging and targeting of suspicious lesions, the new system offers the potential to diagnose serious prostate cancers earlier and follow low-risk cancers more accurately than the standard, two- dimensional, trans rectal ultrasound guided biopsy method.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA176684-02
Application #
8716706
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Henderson, Lori A
Project Start
2013-09-01
Project End
2015-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Emory University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Dormer, James; Qin, Xulei; Shen, Ming et al. (2016) Determining Cardiac Fiber Orientation Using FSL and Registered Ultrasound/DTI volumes. Proc SPIE Int Soc Opt Eng 9790:
Lu, Guolan; Qin, Xulei; Wang, Dongsheng et al. (2016) Quantitative Diagnosis of Tongue Cancer from Histological Images in an Animal Model. Proc SPIE Int Soc Opt Eng 9791:
Pike, Robert; Lu, Guolan; Wang, Dongsheng et al. (2016) A Minimum Spanning Forest-Based Method for Noninvasive Cancer Detection With Hyperspectral Imaging. IEEE Trans Biomed Eng 63:653-63
Liu, Lizhi; Tian, Zhiqiang; Zhang, Zhenfeng et al. (2016) Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications. Acad Radiol 23:1024-46
Lu, Guolan; Qin, Xulei; Wang, Dongsheng et al. (2016) Hyperspectral Imaging of Neoplastic Progression in a Mouse Model of Oral Carcinogenesis. Proc SPIE Int Soc Opt Eng 9788:
Tian, Zhiqiang; Liu, Lizhi; Zhang, Zhenfeng et al. (2016) Superpixel-Based Segmentation for 3D Prostate MR Images. IEEE Trans Med Imaging 35:791-801
Ma, Ling; Guo, Rongrong; Tian, Zhiqiang et al. (2016) Random Walk Based Segmentation for the Prostate on 3D Transrectal Ultrasound Images. Proc SPIE Int Soc Opt Eng 9786:
Ma, Ling; Guo, Rongrong; Tian, Zhiqiang et al. (2016) Combining Population and Patient-Specific Characteristics for Prostate Segmentation on 3D CT Images. Proc SPIE Int Soc Opt Eng 9784:
Chung, Hyunkoo; Lu, Guolan; Tian, Zhiqiang et al. (2016) Superpixel-based spectral classification for the detection of head and neck cancer with hyperspectral imaging. Proc SPIE Int Soc Opt Eng 9788:
Qin, Xulei; Wang, Silun; Shen, Ming et al. (2015) Register cardiac fiber orientations from 3D DTI volume to 2D ultrasound image of rat hearts. Proc SPIE Int Soc Opt Eng 9415:

Showing the most recent 10 out of 34 publications